-
Bolt Technology Corp. (BOLT) Misses Q2 EPS by 415c
-
Bolt Technology Corp. (BOLT) Tops Q1 EPS by 12c
-
Bolt Biotherapeutics (BOLT) Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042
-
H.C. Wainwright Reiterates Neutral Rating on Bolt Biotherapeutics, Inc. (BOLT)
-
Bolt Biotherapeutics, Inc. (BOLT) PT Lowered to $1.25 at Stifel
-
Bolt Technology Corp. (BOLT) Misses Q4 EPS by 6c
-
Bolt Technology Corp. (BOLT) Misses Q3 EPS by 6c
-
Bolt Biotherapeutics (BOLT) Announces Board Changes

